Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Non-Current Assets: 2023-2024

Historic Non-Current Assets for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $20.4 million.

  • Inhibrx Biosciences' Non-Current Assets rose 6.17% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 6.17%. This contributed to the annual value of $20.4 million for FY2024, which is 62.50% up from last year.
  • Inhibrx Biosciences' Non-Current Assets amounted to $20.4 million in FY2024, which was up 62.50% from $12.5 million recorded in FY2023.
  • Inhibrx Biosciences' 5-year Non-Current Assets high stood at $20.4 million for FY2024, and its period low was $12.5 million during FY2023.
  • Over the past 2 years, Inhibrx Biosciences' median Non-Current Assets value was $16.5 million (recorded in 2023), while the average stood at $16.5 million.
  • Data for Inhibrx Biosciences' Non-Current Assets shows a peak YoY skyrocketed of 62.50% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Non-Current Assets (Yearly) stood at $12.5 million in 2023, then soared by 62.50% to $20.4 million in 2024.